Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma-Reference-Cited by-同舟云学术

Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma

Published:2016-08-22 Issue:1 Volume:4 Page:
ISSN:2051-5960
Container-title:Acta Neuropathologica Communications
language:en
Short-container-title:acta neuropathol commun

Author:

Araki Asuka,Chocholous Monika,Gojo Johannes,Dorfer Christian,Czech Thomas,Heinzl Harald,Dieckmann Karin,Ambros Inge M.,Ambros Peter F.,Slavc Irene,Haberler Christine^ORCID

Funder

Oesterreichische Nationalbank

St. Anna Kinderkrebsforschung

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Clinical Neurology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40478-016-0349-9

Reference47 articles.

1. Taylor MD, Poppleton H, Guha A, Gajjar A, Gilbertson RJ. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005;8:323–35. doi: 10.1016/j.ccr.2005.09.001 .

2. McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a Surveillance, Epidemiology, and End Results study. J Neurosurg. 2009;110:725–9. doi: 10.3171/2008.9.JNS08117 .

3. Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ, Barnholtz-Sloan JS. Alex’s Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol. 2015;16 Suppl 10:x1–x36. doi: 10.1093/neuonc/nou327 .

4. Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, Cox T, Chong WK, Campbell RH, Bailey CC, Gattamaneni R, Picton S, Thorpe N, Mallucci C, English MW, Punt JA, Walker DA, Ellison DW, Machin D. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8:696–705. doi: 10.1016/S1470–2045(07)70208–5 .

5. Massimino M, Gandola L, Giangaspero F, Sandri A, Valagussa P, Perilongo G, Garre M-L, Ricardi U, Forni M, Genitori L, Scarzello G, Spreafico F, Barra S, Mascarin M, Pollo B, Gardiman M, Cama A, Navarria P, Brisigotti M, Collini P, Balter R, Fidani P, Stefanelli M, Burnelli R, Potepan P, Podda M, Sotti G, Madon E. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys. 2004;58:1336–45. doi: 10.1016/j.ijrobp.2003.08.030 .

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients;Pediatric Blood & Cancer;2024-01-04

2. Pediatric Central Nervous System Tumor Overview and Emerging Treatment Considerations;Brain Sciences;2023-07-21

3. Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics;Acta Neuropathologica;2023-07-14

4. 3D genome mapping identifies subgroup-specific chromosome conformations and tumor-dependency genes in ependymoma;Nature Communications;2023-04-21

5. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study;Neuro-Oncology;2023-03-14